Answers are grounded in this paper and cite their sources.
• Gynecologic Cancers are a diverse group of malignancies that vary greatly in histologic appearance. • IHC increases diagnostic accuracy leading to precise classification in rare tumor types or challenging cases. • Precision in histologic diagnosis leads to accurate selection of treatment. The use of immunohistochemistry (IHC) and molecular pathology has been widely adopted over the past 3 decades and has aided in the precision of diagnosing gynecologic tumors. While many tumors can be diagnosed by histologic appearance on routine hematoxylin and eosin stained slides, the use of IHC has dramatically changed practice, leading to a better understanding and subtyping of gynecologic tumors. This detailed classification of tumors has aided in the implementation and development of targeted therapies. Available IHC stains and their applications continue to rapidly evolve. Our review aims to provide updated information on the use of IHC in gynecologic tumors. We will also address the rationale for preferred therapeutic regimens that are personalized based on IHC.
No takes yet. Share an insight, caveat, or question.
Katcher et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: